Novartis AG
PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USES THEREOF
Last updated:
Abstract:
The present disclosure relates to prostate specific membrane antigen (PSMA) ligands In particular, the disclosure relates to PSMA ligands having a glutamate-urea-lysine (GUL) moiety, a radioisotope and a chelating agent that can comprise a radiometal.
Status:
Application
Type:
Utility
Filling date:
30 Jun 2020
Issue date:
1 Sep 2022